L8 ANSWER 1 OF 6 USPATFULL on STN

ACCESSION NUMBER:	1999:99651 USPATFULL			
TITLE:	Use of Epinastine for the treatment of pain			
INVENTOR(S):	Jung, Birgit, Schwabenheim, Germany, Federal Republic of Meade, Christopher John Montague, Bingen, Germany, Federal Republic of Pairet, Michel, Biberach, Germany, Federal Republic of			
PATENT ASSIGNEE(S):	Boehringer Indelheim KG, Ingelhiem, Germany, Federal Republic of (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5942503		19990824	<--
	WO 9717971		19970522	<--
APPLICATION INFO.:	US 1998-66392		19980609	(9)
	WO 1996-EP4957		19961113	
			19980609	PCT 371 date
			19980609	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	DE 1995-19542281		19951114	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Jarvis, William R. A.			
LEGAL REPRESENTATIVE:	Raymond, R. P., Devlin, M-E. M., Stempel, A. R.			
NUMBER OF CLAIMS:	11			
EXEMPLARY CLAIM:	1			
LINE COUNT:	401			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 5942503 19990824 <--
WO 9717971 19970522 <--

SUMM . . . symptom. In most cases the headache is of short duration and can readily be controlled by weak analgesics such as **aspirin**, paracetamol or ibuprofen. Such headache is bothersome but does not lead to any significant impairment of health. By contrast, chronic. . .

SUMM . . . high degree of safety for particular patient groups such as children, and patients with reduced liver or kidney function, or **cardiovascular disease**.

DETD When dosed as a tablet or suppository the **single dose** for adults lies between 5 and 200 mg, with the preferred dose between 10 and 50 mg. For inhalation **single doses** between 0.05 and 20 mg, preferably between 0.2 and 5 mg are administered. For parenteral injection the **single dose** lies between 0.1 and 50 mg with a preferred dose between 0.5 and 20 mg. The cited doses may if. . .

DETD Particularly preferred and advantageous appears to be the combination of epinastine with other therapeutic agents, for example **aspirin**, paracetamol, non-steroidal anti-inflammatory drugs (NSAID) such as ibuprofen, meloxicam, indomethacin or naproxen; 5HT.sub.1D agonists such as sumatriptan, MK-462, naratriptan or. . . such as ergotamine, dihydroergotamine or metergoline; clonidine; methysergide; dotarizine; lisuride; pizotifen; valproic acid; aminotryptiline; beta blockers such as propanolol or **metoprolol**; calcium channel antagonists such as flunarizine or lomerizine, or neurokinin antagonists. Such a combination, either in a **single dosage** form or in separate forms able to be administered sequentially or substantially simultaneously, comprises a further feature of the invention.

CLM What is claimed is:

. . . wherein the further analgesic used is an NSAID, a 5HT.sub.1D -agonist, a dopamine D.sub.2 receptor antagonist, an ergot alkaloid, a

beta blocker, a calcium channel blocker or a neurokinin antagonist.

9. The method according to claim 4, in which the **beta-blocker** is propoanolol or **metoprolol**.

11. The method according to claim 3, in which the analgesia-producing agent that is combined is **aspirin**, paracetamol, clonidine, methysergide, dotarizine, lisuride, pizotifen, valproic acid, aminotryptiline, CP-122,288 or UK 116,044.

L8 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER:	1998:124584 USPATFULL
TITLE:	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
INVENTOR(S):	Medford, Russell M., Atlanta, GA, United States Offermann, Margaret K., Atlanta, GA, United States Alexander, R. Wayne, Atlanta, GA, United States Parthasarathy, Sampath, Atlanta, GA, United States
PATENT ASSIGNEE(S):	Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5821260		19981013	<--
APPLICATION INFO.:	US 1995-485307		19950607 (8)	

RELATED APPLN. INFO.: Division of Ser. No. US 1994-240858, filed on 10 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	O'Sullivan, Peter
LEGAL REPRESENTATIVE:	Knowles, Sherry M., Haley, JacquelineKing & Spalding
NUMBER OF CLAIMS:	16
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:	1413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 5821260 19981013 <--

AB . . . block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of **cardiovascular disease**, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.

SUMM Current therapies for **cardiovascular disease**, and in particular, atherosclerosis do not treat the cause of the disease, but instead treat the symptoms of the disease. . . associated with the disease. Pharmaceutical agents prescribed for these conditions include lipid lowering agents such as probucol and nicotinic acid; **aspirin** (which prevents platelets from sticking); antithrombotic agents such as coumadin; calcium channel blockers such as varapamil, diltiazem, and nifedipine; angiotensin. . .

SUMM Given that **cardiovascular disease** is currently the leading cause of death in the United States, and ninety percent of **cardiovascular disease** is presently diagnosed as atherosclerosis, there is a strong need to identify new methods and pharmaceutical agents for its treatment.

SUMM The compounds described herein are useful in both the primary and adjunctive medical treatment of **cardiovascular disease** . The compounds are used in primary treatment of, for example, coronary

disease states including atherosclerosis, post-angioplasty restenosis, coronary artery diseases,. . .

SUMM . . . to reduce the risk of disease by lowering LDL and serum cholesterol. The method represents a significant advance in treating **cardiovascular disease**, in that it goes beyond the current therapies designed simply to inhibit the progression of the disease, and when used. . .

SUMM . . . from once every other day to twice to several times a day. The length of dosing will range from a **single dose** given only once to twice daily dosages given over the course of two to six months.

SUMM The active compounds can be administered in conjunction with other medications used in the treatment of **cardiovascular disease**, including lipid lowering agents such as probucol and nicotinic acid; platelet aggregation inhibitors such as **aspirin** ; antithrombotic agents such as coumadin; calcium channel blockers such as varapamil, diltiazem, and nifedipine; angiotensin converting enzyme (ACE) inhibitors such. . .

DETD . . . B will also have an important effect on the tissue-distribution and pharmacokinetics of the compound. In general, for treatment of **cardiovascular disease**, it is desirable that the compound accumulate, or localize, in the arterial intimal layer containing the vascular endothelial cells. The. . .

DETD . . . the treatment, cure, or prevention of a disease or disorder. Nonlimiting examples are drugs for the treatment or prevention of **cardiovascular disease**, including antioxidants such as probucol; nicotinic acid; agents that prevent platelets from sticking, such as **aspirin**; antithrombotic agents such as coumadin; calcium channel blockers such as varapamil, diltiazem, and nifedipine; angiotensin converting enzyme (ACE) inhibitors such. . .

DETD . . . The compound should not compartmentalize in low turnover regions such as fat deposits. In a preferred embodiment for treatment of **cardiovascular disease**, the pharmacokinetics of the compound should not be dramatically affected by congestive heart failure or renal insufficiency.

DETD . . . which specifically includes the use of any of the above-described compounds to treat atherosclerosis, and other types of inflammation and **cardiovascular disease** mediated by VCAM-1. Any of the compounds described above can be easily substituted for PDTC and evaluated in similar fashion.

DETD . . . active compounds can be administered with lipid lowering agents such as probucol and nicotinic acid; platelet aggregation inhibitors such as **aspirin**; antithrombotic agents such as coumadin; calcium channel blockers such as varapamil, diltiazem, and nifedipine; angiotensin converting enzyme (ACE) inhibitors such. . . as propanalol, terbutalol, and labetalol. The compounds can also be administered in combination with nonsteroidal antiinflammatories such as ibuprofen, indomethacin, **aspirin**, fenoprofen, mefenamic acid, flufenamic acid, sulindac. The compound can also be administered with corticosteriods.

CLM What is claimed is:

1. A method for the treatment of a **cardiovascular disease** in humans comprising administering an effective amount of a dithiocarbamate of the formula A--SC(S)--B; wherein A is selected from the. . .

8. The method of claim 1, wherein the **cardiovascular disease** is atherosclerosis.

9. The method of claim 1, wherein the **cardiovascular disease** is post-angioplasty restenosis.

10. The method of claim 1, wherein the **cardiovascular disease** is coronary artery disease.

11. The method of claim 1, wherein the **cardiovascular disease** is angina.

12. The method of claim 1, wherein the **cardiovascular disease** is a small vessel disease.

. . . of a, a platelet aggregation inhibitor, an antithrombotic agent, a calcium channel blocker, an angiotensin converting enzyme (ACE) inhibitor, a .**beta**.-**blocker**, a nonsteroidal antiinflammatory, and a corticosteroid.

16. A method for the treatment of a **cardiovascular disease** in humans comprising administering an effective amount of a dithiocarbamate of the formula B--C(S)S--SC(S)--B wherein B is selected form the. . .

L8 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER:	93:78774 USPATFULL
TITLE:	Thiadiazinones for stimulating cardiac activity
INVENTOR(S):	Coates, William J., Welwyn Garden City, England
PATENT ASSIGNEE(S):	Smith Kline & French Laboratories Limited, Welwyn Garden City, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5246928		19930921	<--
APPLICATION INFO.:	US 1991-727774		19910710 (7)	
RELATED APPLN. INFO.:	Division of Ser. No. US 1989-452072, filed on 18 Dec 1989, now patented, Pat. No. US 5066653 which is a division of Ser. No. US 1986-918425, filed on 14 Oct 1986, now patented, Pat. No. US 4906628, issued on 6 Mar 1990			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Shah, Mukund J.			
ASSISTANT EXAMINER:	Grumbling, Matthew V.			
LEGAL REPRESENTATIVE:	McCarthy, Mary E., Venetianer, Stephen, Lentz, Edward T.			
NUMBER OF CLAIMS:	13			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1066			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 5246928 19930921 <--

SUMM . . . beneficial. Thus the compounds of this invention are positive inotropic agents and vasodilators and are therefore of value in combatting **cardiovascular disease**, in particular congestive heart failure. In addition the compounds of this invention inhibit platelet aggregation and therefore have an antithrombotic. . .

SUMM . . . dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a **single dose**.

DETD In anaesthetised cats pretreated with a ganglion blocker (mecamylamine or pempidine) and **propranolol**, the compounds of the Examples cause increases in left ventricular dp/dt max (this is an index of left ventricular contractility). . .

DETD **Aspirin** was added to a concentration of 100 μM.

DETD The compound of Example 1 inhibited aggregation induced by the endoperoxide mimetic U44069 (10 μM) in **aspirin**-treated platelet rich plasma with an IC.sub.50 value of 0.08±0.01 μM.

L8 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER:	91:94551 USPATFULL

TITLE: Chemical compounds
INVENTOR(S): Coates, William J., Welwyn Garden City, England
PATENT ASSIGNEE(S): Smith Kline & French Laboratories Limited, Welwyn Garden City, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5066653		19911119	<--
APPLICATION INFO.:	US 1989-452072		19891218	(7)

RELATED APPLN. INFO.: Division of Ser. No. US 1986-918425, filed on 14 Oct 1986, now patented, Pat. No. US 4906628

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-25654	19851017
	GB 1986-1667	19860123

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Berch, Mark L.
LEGAL REPRESENTATIVE: McCarthy, Mary E., Suter, Stuart R., Lentz, Edward T.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1,7,8,9,10
LINE COUNT: 1044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5066653 19911119 <--
SUMM . . . beneficial. Thus the compounds of this invention are positive inotropic agents and vasodilators and are therefore of value in combatting **cardiovascular disease**, in particular congestive heart failure. In addition the compounds of this invention inhibit platelet aggregation and therefore have an antithrombotic. . .
SUMM . . . dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a **single dose**.
DETD In anaesthetised cats pretreated with a ganglion blocker (mecamylamine or pempidine) and **propranolol**, the compounds of the Examples cause increases in left ventricular dp/dt max (this is an index of left ventricular contractility). . .
DETD **Aspirin** was added to a concentration of 100 μM.

L8 ANSWER 5 OF 6 USPATFULL on STN
ACCESSION NUMBER: 90:17677 USPATFULL
TITLE: N-phenylpyridone type III phosphodiesterases
INVENTOR(S): Coates, William J., Welwyn Garden City, England
PATENT ASSIGNEE(S): Smith Kline & French Laboratories Limited, Welwyn Garden City, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4906628		19900306	<--
APPLICATION INFO.:	US 1986-918425		19861014	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-25654	19851017
	GB 1986-1667	19860123

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Berch, Mark L.
LEGAL REPRESENTATIVE: McCarthy, Mary E., Suter, Stuart R., Lourie, Alan D.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1,5,12
LINE COUNT: 1059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 4906628 19900306 <--
SUMM . . . beneficial. Thus the compounds of this invention are positive inotropic agents and vasodilators and are therefore of value in combatting **cardiovascular disease**, in particular congestive heart failure. In addition the compounds of this invention inhibit platelet aggregation and therefore have an antithrombotic. . .
DETD . . . dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a **single dose**.
DETD In anaesthetised cats pretreated with a ganglion blocker (mecamylamine or pempidine) and **propranolol**, the compounds of the Examples cause increases in left ventricular dp/dt max (this is an index of left ventricular contractility). . .
DETD **Aspirin** was added to a concentration of 100 μM.

L8 ANSWER 6 OF 6 USPATFULL on STN
ACCESSION NUMBER: 89:5927 USPATFULL
TITLE: Sustained release method and product
INVENTOR(S): Hom, Foo S., Safety Harbor, FL, United States
Ebert, William R., St. Petersburg, FL, United States
PATENT ASSIGNEE(S): R. P. Scherer Corporation, Troy, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4800083		19890124	<--
APPLICATION INFO.:	US 1986-921069		19861020	(6)

DISCLAIMER DATE: 20010131
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Alllegretti & Witcoff, Ltd.
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 4800083 19890124 <--
DETD . . . include quinidine sulfate (such as in Quinidex Extentabs by A. H. Robins), nitroglycerin (such as Nitrostat SR capsules by Parke-Davis), **propranolol** hydrochloride (such as inderal by Ayerst), and nifedipine (such as in Procardia by Pfizer). Suitable antiasthmatics or antitussives include theophylline. . . as Hydro Diuril tablets by Merck, Sharp & Dohme). Analgesics and antipyretics useful in our sustained release drug form include **aspirin** and indomethacin (such as Indocin SR capsules by Merck Sharp & Dohme). Suitable antimotion sickness and antinauseants include meclizine hydrochloride. . .
DETD . . . for example, some drugs may cause nausea or bleeding by irritation of the gastric mucosa. Examples of such drugs are **aspirin** and steroids. Useful enteric coatings in manufacturing our coated drug forms include hydroxypropylmethylcellulose phthalate, cellulose acetate phthalate, polyvinyl acetate phthalate,. . .
DETD . . . sustained release dosage formulation of the present invention as compared to an immediately released theophylline product following administration of a **single dose**. The capsules utilized were the 300 milligram sustained release theopylline capsule as described above having a preferred fill material of. . .
DETD . . . and a weight of greater than or equal to 125 lbs.; (c) no history of serious hepatic, renal, gastrointestinal or **cardiovascular disease**, alcohol or drug abuse, as evidenced by a medical history, physical examination and vital signs within 30 days prior to. . .

DETD TABLE I

Comparison of AUC's for Human Subjects Receiving a **Single Dose**, 300 mg, of Elixir of Theophylline (Berlex Labs. Inc.) and Sustained Release Capsules of Theophylline (R.P. Scherer)

Sample	Subject 1	2	4	5	7.	.	.

DETD The **single dose** study of Example I served as the pre-test dose evaluation for the multiple dose, steady state study. The subjects were. . .

DETD Dissolution studies were performed on soft gelatin capsules containing a fill material made in accordance with the invention and containing **Propranolol** HCl as set forth below. The shell formulation was conventional and was composed of gelatin and glycerin, in major proportion,. . .

DETD

Fill Ingredients	mg/Capsule
Propranolol HCl (Cardiovascular/ Antihypertensive Drug)	120
Chewing Gum Base	210
Wecobee M**	200
Purified Stearic Acid	70
Neutral Oil	30
	630

DISSOLUTION (N = 6)

TIME, hr	MEAN.	.	.

CLM What is claimed is:

13. The capsule of claim 1 wherein said medicament is **propranolol**.

27. The method of claim 15 wherein said medicament is **propranolol**.

38. The capsule of claim 29 wherein the medicament is **propranolol**.

48. The method of claim 40 wherein said medicament is **propranolol**.

=> d his

(FILE 'HOME' ENTERED AT 13:49:11 ON 21 DEC 2005)

FILE 'STNGUIDE' ENTERED AT 13:52:37 ON 21 DEC 2005

FILE 'HOME' ENTERED AT 13:52:42 ON 21 DEC 2005

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, PASCAL, ...' ENTERED AT 13:52:53 ON 21 DEC 2005

L1 1040713 S CARDIOVASCULAR DISEASE
L2 470962 S BETA BLOCKER OR PROPRANOLOL OR TIMOLOL OR METOPROLOL OR PINDO
L3 296487 S PLATELET INHIBITOR OR ASPIRIN

L4	980	S L1 AND L2 AND L3
L5	880	DUP REM L4 (100 DUPLICATES REMOVED)
L6	879	S L5 AND ASPIRIN
L7	121	S L6 AND SINGLE DOS?
L8	6	S L7 AND PD<2000